259.85
+1.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ascendis Pharma A/S
Its shares trade under the ticker ASND. It has been listed since 28 January 2015. In the fiscal year to 31 December 2025, it reported revenue of €808.0m and a net loss of €255.9m. At that date it held total assets of €1.52bn and shareholders' equity of −€190.1m.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The firm is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Jan 2015
- Employees
- 1,189
- Website
- ascendispharma.com ↗
- Head office
- TUBORG BOULEVARD 12, HELLERUP
- Incorporated in
- G7
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Albert ChaIndependent Chairman of the Board€139,721
- Mr. Jan Moller MikkelsenPresident, Chief Executive Officer, Executive Director, Member of the Executive Board, since 2007
- Mr. Scott SmithChief Financial Officer, Executive Vice President, Member of the Executive Board
- Ms. Lotte SoenderbjergExecutive Vice President, Chief Administrative Officer, Member of the Executive Board
- Mr. Michael JensenExecutive Vice President, Chief Legal Officer, Member of the Executive Board, since 2008
- Mr. Flemming JensenExecutive Vice President, Product Supply and Quality
- Dr. Aimee Shu,Executive Vice President, Chief Medical Officer
- Dr. Stina SingelExecutive Vice President, Head of Clinical Development, Oncology
- Dr. Kennett SprogoeeExecutive Vice President, Head of Innovation and Research
- Mr. Donovan WuExecutive Vice President, U.S. President
- Mr. Mads BodenhoffSenior Vice President, Head of Finance and Principal Accounting Officer
- Ms. Lisa BrightIndependent Director€92,644
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 35
- Social
- 99
- Governance
- 36
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ascendis Pharma A/S boasts a strong and innovative product portfolio, which includes several potential breakthrough treatments in the biopharmaceutical industry. The company's focus on developing novel therapies for rare diseases positions them as a leading player in this niche market segment.
- Ascendis Pharma A/S has established strategic partnerships and collaborations with prominent pharmaceutical companies and research institutions. These alliances provide access to additional resources, expertise, and funding, enhancing the company's research and development capabilities.
Weaknesses
- The company's success heavily relies on the performance and approval of its key products in the pipeline. Any setbacks or delays in their development or regulatory processes could significantly impact Ascendis Pharma A/S's financial stability and growth prospects.
- As a biopharmaceutical company operating in a highly regulated industry, Ascendis Pharma A/S faces inherent risks associated with compliance, clinical trials, and regulatory approvals. Any failure to meet regulatory requirements or unexpected safety concerns may hinder product development and market access.
Opportunities
- The increasing prevalence and awareness of rare diseases present a significant opportunity for Ascendis Pharma A/S. The company's focus on developing targeted therapies for such conditions allows them to tap into an underserved market and potentially achieve substantial market share.
- Ascendis Pharma A/S has the potential to expand its presence in international markets. By leveraging strategic partnerships and collaborations, the company can explore new geographic regions, access diverse patient populations, and capitalize on the global demand for innovative treatments.
Threats
- Ascendis Pharma A/S faces significant competition from established pharmaceutical companies in the rare disease space. These competitors may have greater financial resources, established market presence, and a wider range of product offerings, posing a challenge to Ascendis Pharma A/S's market position.
- The biopharmaceutical industry is subject to economic and market fluctuations. Economic downturns, changes in healthcare policies, or shifts in consumer buying patterns can impact Ascendis Pharma A/S's revenue streams and hinder its growth potential.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.